Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ex vivo generated megakaryocytic
progenitor cells (MPs) in prophylaxis and treatment of thrombocytopenia caused by
chemotherapy in patients with acute leukemia (AL).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
Academy Military Medical Science, China Guangdong General Hospital Guangdong Provincial People's Hospital Guangzhou First Municipal People’s Hospital Guangzhou First People's Hospital Guangzhou General Hospital of Guangzhou Military Command Huazhong University of Science and Technology Peking University People's Hospital Southern Medical University, China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Sun Yat-sen University Third Affiliated Hospital, Sun Yat-Sen University